fbpx
01 / 05
Alexandria Ends Single-Family-Only Zoning

The Washington Post | Housing

Alexandria Ends Single-Family-Only Zoning

“Alexandria lawmakers voted unanimously early Wednesday to eliminate single-family-only zoning in this Northern Virginia city, a functionally limited but symbolic and controversial move that opens the door for the construction of buildings with as many as four units in any residential neighborhood.”

From The Washington Post.

S&P Global | Energy & Natural Resources

US DOE Finalizes Rules to Speed Transmission Permitting

“Under the program, the DOE will coordinate efforts across eight other agencies to prepare a single environmental review document for transmission developers seeking federal approvals. The program also establishes a two-year timeline for the permitting process.

‘The CITAP program gives transmission developers a new option for a more efficient review process, a major step to provide increased confidence for the sector to invest in new transmission lines,’ the DOE said in a fact sheet.

A second final rule creates a categorical exclusion — the simplest form of review under the National Environmental Policy Act — for transmission projects that use existing rights of way, such as reconductoring projects, as well as solar and energy storage projects on already disturbed lands.”

From S&P Global.

Washington Post | Health & Medical Care

FDA Authorizes AI-Driven Test to Predict Sepsis in Hospitals

“Bobby Reddy Jr. roamed a hospital as he built his start-up, observing how patient care began with a diagnosis and followed a set protocol. The electrical engineer thought he knew a better way: an artificial intelligence tool that would individualize treatment.

Now, the Food and Drug Administration has greenlighted such a test developed by Reddy’s company, Chicago-based Prenosis, to predict the risk of sepsis — a complex condition that contributes to at least 350,000 deaths a year in the United States. It is the first algorithmic, AI-driven diagnostic tool for sepsis to receive the FDA’s go-ahead.”

From Washington Post.